Preliminary data from Parse’s chromatin assay showing clustering of mouse brain nuclei based on DNA accessibility profiles. (Graphic: Business Wire)
Parse Biosciences, the leader in accessible and scalable single cell sequencing, today affirmed their plans to proceed with development and future release of their Evercode™ single cell chromatin products. This comes on the heels of Parse invalidating the patents that 10x Genomics had asserted against Parse’s Evercode Whole Transcriptome products and the subsequent cancellation of a trial on those patents. In connection with these events, Parse reached a favorable resolution with 10x Genomics over other patents that are unrelated to either Parse’s existing Evercode products or its forthcoming chromatin accessibility products.
Parse’s chromatin accessibility technology leverages a novel approach with advantages over existing methods such as ATAC-seq and will deliver higher quality, more uniform data. Parse plans to make their new solutions available for early access in late 2025.
Parse’s latest innovations include the recent launch of their Evercode Penta kit, the largest ever single cell sequencing kit that allows researchers to look at up to 5 Million cells in a single experiment.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304469003/en/
출처: Parse Biosciences
언론연락처: Parse Biosciences Kaitie Kramer 858.504.0455
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
